INTRODUCTION
Tumor-node-metastasis (TNM) cancer staging was devel- Prior to the novel revision of esophageal cancer described in this paper, the criteria for T, N, and M classifications had not changed since 1988, 1977 , and 1997, respectively. The long-held concept of stage groupings of esophageal cancer has been a hindrance to the evolution of esophageal cancer staging, because this concept is incorrectly based on a simple, orderly arrangement of increasing anatomic T, then N, then M classifications. This assumption is not consistent with cancer biology or survival data. Worldwide collaboration [1] has provided data for a novel modern machine-learning analysis [2] that has produced data-driven staging for cancers of the esophagus and esophagogastric junction [3] . This new system is the basis for the seventh editions of the AJCC and UICC Cancer Staging Manuals [4, 5] . It is more representative of and consistent with the survival rates of patients who undergo esophagectomy for esophageal cancer, and incorporates changes that address some difficulties in empirical stage grouping and previous areas of disharmony with stomach cancer staging [6] T is classified as follows: Tis, high-grade dysplasia (HGD); T1, cancer invades lamina propria, muscularis mucosae, or submucosa; T2, cancer invades muscularis propria; T3, cancer invades adventitia; T4a, resectable cancer invading adjacent structures such as pleura, pericardium, or diaphragm; and T4b, unresectable cancer invading other adjacent structures, such as the aorta, vertebral body, or trachea. The N classifications are as follows: N0, no regional lymph node metastasis; N1, regional lymph node metastases involving one to two nodes; N2, regional lymph node metastases involving three to six nodes; and N3, regional lymph node metastases involving seven or more nodes. M is classified as follows: M0, no distant metastasis; and M1, distant metastasis. Instead, the staging introduced in the seventh edition used random forest (RF) analysis, a machine learning technique that focuses on predictiveness for future patients [2] . RF analysis makes no a priori assumptions about patient survival, is able to identify complex interactions among variables, and accounts for nonlinear effects. It may be viewed as a backward analysis that determines the anatomic classifications (TNM) and nonanatomic cancer characteristics that are associated with specific survival groups.
The RF analysis employed in this process first isolated cancer characteristics of interest from other factors that influence survival by generating risk-adjusted survival curves for each patient. Unlike previous approaches that began by placing cancer characteristics into proposed groups, RF analysis produced distinct groups with monotonically decreasing risk-adjusted survival rates without regard to cancer characteristics.
Subsequently, anatomic and nonanatomic cancer characteristics important for the composition of stage groups were identified within the groups produced by RF analysis. Finally, the principle of assuring homogeneity within groups guided both the amalgamation and segmentation of cancer characteristics between adjacent groups to arrive at the final stage groupings [3] [4] [5] .
SEVENTH EDITION TNM CLASSIFICATIONS: CHANGES AND ADDITIONS
The primary tumor (T) classification has been changed for Tis and T4 cancers (Fig. 1 , Table 1 Table 1 ).
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− 159 − Includes all non-invasive neoplastic epithelium that was previously called carcinoma in situ. Cancers stated to be non-invasive or in situ are classified as Tis. Number must be recorded for total number of regional nodes sampled and total number of reported nodes with metastases. A regional lymph node has been redefined to include any paraesophageal lymph node that extends from the cervical nodes to celiac nodes ( Table 1) (Table 1) . Distant metastasis is simply classified as M0, indicating no distant metastasis, and M1, indicating distant metastasis [7] .
SEVENTH EDITION: NONANATOMIC CANCER CHARACTERISTICS
The nonanatomic classifications identified as important for stage grouping (Table 1 ) are the histopathologic cell type, histologic grade, and tumor location (Fig. 2) . The difference in survival between adenocarcinoma and squamous cell carcinoma is best captured by including separate stage groupings for stages I and II. Increasing histologic grade is associated with incrementally decreasing survival for early-stage cancers.
For adenocarcinoma, it is important to distinguish G1 and G2
(well differentiated and moderately differentiated) from G3 (poorly differentiated) for stage I and stage IIA cancers. For squamous cell carcinoma, distinguishing G1 from G2 and G3 Thomas W. Rice − 160 − Fig. 2 . Cancer location. The cervical esophagus, bounded superiorly by the cricopharyngeus and inferiorly by the sternal notch, is typically 15-20 cm from the incisors using esophagoscopy. The upper thoracic esophagus, bounded superiorly by the sternal notch and inferiorly by the azygos arch, is typically 20-25 cm from the incisors using esophagoscopy. The middle thoracic esophagus, bounded superiorly by the azygos arch and inferiorly by the inferior pulmonary vein, is typically 25-30 cm from the incisors using esophagoscopy. The lower thoracic esophagus, bounded superiorly by the inferior pulmonary vein and inferiorly by the lower esophageal sphincter, is typically 30-40 cm from the incisors using esophagoscopy; this location includes cancers whose epicenter is within the proximal 5 cm of the stomach that extend into the EGJ or lower thoracic esophagus. EGJ, esophagogastric junction. Stage 0, III, and IV adenocarcinomas (Fig. 3) and squamous cell carcinomas (Fig. 4B) 
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SURVIVAL
In the seventh edition classification, survival monotonically decreases with increasing stage groupings, and survival rates are markedly different among the groups (Fig. 5) . However, due to rigid stage grouping definitions and limitations of the data, homogeneous survival rates are not seen in all groups (Fig. 6 ). Despite these shortcomings, the seventh edition represents a major evolutionary step in esophageal cancer staging. The risk-adjusted survival curves contained in the seventh edition can be used, with a recognition of their limitations, for crude prediction of the survival rate of various groups of patients. 
THE FUTURE: THE EIGHTH EDITION AND BEYOND
The seventh edition heralded the era of data-driven cancer staging [8] . However, the seventh edition was derived from data that only reflected patients who underwent esophagectomy, which is an obvious shortcoming. The following steps will be necessary for improving the next iterations of esophageal cancer staging:
(1) Obtaining better homogeneity within stage 0 and stage IV (Fig. 6 ). This will require abandoning the restrictive definitions of these stage groupings and changing the composition of the adjacent stage IA and stage IIIC groupings.
(2) Improving the homogeneity of stage IIB adenocarcinoma ( Fig. 6A ) and stage IIA and IIB squamous cell cancer (Fig. 6B ). This will require expanding the database of these less common cancers. The acquisition of international multicenter data through the Worldwide Esophageal Cancer Collaboration is key to this effort [1] . Innovative machine learning techniques will again be used for analyzing the data [2] . The strategy for adding clinical, post-induction and definitive nonoperative therapy clinical, and post-induction pathologic staging will be to reference these stages to the pStaging platform of the eighth edition [9] .
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